Last reviewed · How we verify

Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole

University of Chicago · FDA-approved active Small molecule

This is a combination therapy regimen using ibuprofen (NSAID), hydrocodone/acetaminophen (opioid/analgesic), and omeprazole (proton pump inhibitor) to manage pain while protecting the gastrointestinal tract.

This is a combination therapy regimen using ibuprofen (NSAID), hydrocodone/acetaminophen (opioid/analgesic), and omeprazole (proton pump inhibitor) to manage pain while protecting the gastrointestinal tract. Used for Moderate to severe pain with gastroprotection, Chronic pain conditions requiring NSAID therapy with acid suppression.

At a glance

Generic nameIbuprofen, Hydrocodone/Acetaminophen, Omeprazole
Also known asMotrin, Advil (Ibuprofen), Norco (Hydrocodone/Acetaminophen), Prilosec (Omeprazole)
SponsorUniversity of Chicago
Drug classNSAID + opioid analgesic + proton pump inhibitor combination
TargetCOX-1/COX-2 (ibuprofen); mu-opioid receptor (hydrocodone); H+/K+-ATPase (omeprazole)
ModalitySmall molecule
Therapeutic areaPain Management / Gastroenterology
PhaseFDA-approved

Mechanism of action

Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain. Hydrocodone is an opioid agonist that binds mu-opioid receptors for analgesia, combined with acetaminophen which inhibits prostaglandin synthesis. Omeprazole suppresses gastric acid secretion by inhibiting the H+/K+-ATPase pump to reduce GI ulceration risk from chronic NSAID use.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: